Authors:
Lali Pkhaladze, Zdravko Kamenov, Maurizio Nordio, Samuel H. Myers, Vittorio Unfer
Introduction
Inositol has increasingly come under the spotlight as research into its biological function and applications has continued to increase. Currently, inositol is utilized as an insulin sensitizer in a similar manner to metformin in the field of polycystic ovary syndrome (PCOS) and is also known to be involved in steroidogenesis [1]. Consequently, it was mentioned within the recently published international clinical guidelines on PCOS albeit still as an experimental therapy [2].
These guidelines were discussed at length, alongside other major topics at the ISGE Gynecological Endocrinology 21st world conference that was held in Florence Italy between the 8th and 11th May. During the conference, the Expert Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS) hosted a session to discuss recent progress in inositol research within the field of PCOS and to celebrate 4 years since the founding of the EGOI. Established with the mission of exploring the key physiological functions and clinical applications of inositol across a variety of disease areas, the EGOI has expanded to include international experts from various disciplines such as gynecology and endocrinology.
In the last year, PCOS has emerged to be the primary focus of the group, particularly the metabolic aspect of this condition, leading to the incorporation of
the syndrome within the name of the society.
Herein, we describe the talks given during the EGOIPCOS session with the aim to stimulate further research into the applications of myo-inositol. Finally, we would like to express our deepest gratitude to all the session’s participants, whose collaboration and engagement helped foster a dynamic and enlightening meeting.
